JP2023542521A - ループス腎炎（ｌｎ）及び／又はｉｇａ腎症（ｉｇａｎ）を含むｃ５媒介性糸球体腎炎（ｇｎ）の治療のための抗ｃ５抗体の投与量及び投与 - Google Patents

ループス腎炎（ｌｎ）及び／又はｉｇａ腎症（ｉｇａｎ）を含むｃ５媒介性糸球体腎炎（ｇｎ）の治療のための抗ｃ５抗体の投与量及び投与 Download PDF

Info

Publication number
JP2023542521A
JP2023542521A JP2023518165A JP2023518165A JP2023542521A JP 2023542521 A JP2023542521 A JP 2023542521A JP 2023518165 A JP2023518165 A JP 2023518165A JP 2023518165 A JP2023518165 A JP 2023518165A JP 2023542521 A JP2023542521 A JP 2023542521A
Authority
JP
Japan
Prior art keywords
dose
once
day
weeks
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542521A5 (https=
Inventor
ネーダー ナジャフィアン，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023542521A publication Critical patent/JP2023542521A/ja
Publication of JP2023542521A5 publication Critical patent/JP2023542521A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023518165A 2020-09-21 2021-09-16 ループス腎炎（ｌｎ）及び／又はｉｇａ腎症（ｉｇａｎ）を含むｃ５媒介性糸球体腎炎（ｇｎ）の治療のための抗ｃ５抗体の投与量及び投与 Pending JP2023542521A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063081182P 2020-09-21 2020-09-21
US63/081,182 2020-09-21
PCT/US2021/050590 WO2022060931A1 (en) 2020-09-21 2021-09-16 Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan)

Publications (2)

Publication Number Publication Date
JP2023542521A true JP2023542521A (ja) 2023-10-10
JP2023542521A5 JP2023542521A5 (https=) 2024-09-25

Family

ID=78087569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518165A Pending JP2023542521A (ja) 2020-09-21 2021-09-16 ループス腎炎（ｌｎ）及び／又はｉｇａ腎症（ｉｇａｎ）を含むｃ５媒介性糸球体腎炎（ｇｎ）の治療のための抗ｃ５抗体の投与量及び投与

Country Status (10)

Country Link
US (1) US20230348579A1 (https=)
EP (1) EP4213940A1 (https=)
JP (1) JP2023542521A (https=)
KR (1) KR20230073261A (https=)
CN (1) CN116261569A (https=)
AU (1) AU2021344411A1 (https=)
CA (1) CA3173003A1 (https=)
IL (1) IL301350A (https=)
MX (1) MX2023003256A (https=)
WO (1) WO2022060931A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025166118A1 (en) 2024-02-02 2025-08-07 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023564A1 (en) * 2017-07-27 2019-01-31 Alexion Pharmaceutical, Inc. ANTI-C5 ANTIBODY FORMULATIONS WITH HIGH CONCENTRATION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023564A1 (en) * 2017-07-27 2019-01-31 Alexion Pharmaceutical, Inc. ANTI-C5 ANTIBODY FORMULATIONS WITH HIGH CONCENTRATION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DRUGS, vol. 79, JPN6025042691, 2019, pages 347 - 352, ISSN: 0005710248 *

Also Published As

Publication number Publication date
CN116261569A (zh) 2023-06-13
EP4213940A1 (en) 2023-07-26
AU2021344411A9 (en) 2024-09-26
IL301350A (en) 2023-05-01
AU2021344411A1 (en) 2023-04-27
KR20230073261A (ko) 2023-05-25
MX2023003256A (es) 2023-04-11
WO2022060931A1 (en) 2022-03-24
US20230348579A1 (en) 2023-11-02
CA3173003A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
US20250066466A1 (en) Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
TWI616204B (zh) Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
JP7577542B2 (ja) 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
JP2023101717A (ja) 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与
KR20210119420A (ko) 비정형 용혈성 요독증후군(ahus)의 치료를 위한 항-c5 항체의 복용량 및 투여
KR20220149740A (ko) Pd-1 길항제, ctla4 길항제 및 렌바티닙 또는 그의 제약상 허용되는 염의 조합물을 사용하여 암을 치료하는 방법
JP2026026191A (ja) 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与
US12497449B2 (en) Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
WO2022087339A1 (en) Methods of treating patients having complement disorders using anti-c5 antibodies
JP2023542521A (ja) ループス腎炎（ｌｎ）及び／又はｉｇａ腎症（ｉｇａｎ）を含むｃ５媒介性糸球体腎炎（ｇｎ）の治療のための抗ｃ５抗体の投与量及び投与
KR20230048422A (ko) 오크렐리주맙으로 다발성 경화증을 치료하는 방법
JP2024521474A (ja) 皮膚筋炎（ｄｍ）を治療するための抗ｃ５抗体の投与量及び投与
WO2025166118A1 (en) Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan)
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260416